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Abstract
Background: The effects of vitamin D supplementation on mild hepatic dysfunction and glycemic control are unclear in
children and adolescents with either type 1 (T1D) or type 2 diabetes (T2D).
Hypothesis: Vitamin D supplementation will improve hepatic dysfunction and glycemic control.
Aim: To determine the effect of vitamin D supplementation on alanine transaminase (ALT), hemoglobin A1c (HbA1c), and
serum 25-hydroxyvitamin D [25(OH)D] concentration.
Subjects and Methods: A retrospective study of 131 subjects with either T1D (n = 88:46 females, 42 males), or T2D (n = 43:26
females, 17 males) of ages 3–18 years between 2007–2013. All subjects had (1) a diagnosis of diabetes for .12 mo, (2)
received vitamin D supplementation for the management of vitamin D deficiency (3) had baseline and subsequent
simultaneous measurements of HbA1c, ALT, and 25(OH)D. Vitamin D deficiency was defined as 25(OH)D concentration of ,
50 nmol/L (20 ng/mL).
Results: At baseline, vitamin D deficiency occurred in 72.1% of patients with T2D and in 37.5% of T1D patients (p,0.001).
Patients with T2D had significantly higher values for BMI SDS (p,0.001), alanine transaminase (ALT) (p = 0.001), but lower
25(OH)D (p,0.001), and no difference in HbA1c (p = 0.94), and total daily dose (TDD) of insulin per kg body weight (p = 0.48)
as compared to T1D patients. After 3 months of vitamin D supplementation, there was a significant increase in 25(OH)D in
both T2D (p = 0.015), and T1D patients (p,0.001); significant reduction in BMI SDS (p = 0.015) and ALT (p = 0.012) in T2D, but
not in T1D. There was a clinically-significant decrease in HbA1c in T2D from 8.562.9% at baseline to 7.762.5 at 3 mo, but
not in T1D, 8.561.2 to 8.5361.1%.
Conclusions: Vitamin D supplementation in subjects with T2D was associated with statistically significant decreases in BMI
SDS, ALT, and a clinically-significant decrease in HbA1c.
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Introduction
The management of diabetes mellitus remains an enigma even
though its symptoms were described more than 2000 years ago.
This is because the central therapeutic goal of diabetes manage-
ment, euglycemia, is influenced by complex physiologic and
pathologic processes, some of which are clearly understood, while
others are less clear. Suboptimal glycemic control is a recognized
risk factor for acute and chronic complications of diabetes
including microvascular and macrovascular diseases [1–3]. How-
ever, the role of comorbid states such as nonalcoholic fatty liver
disease (NAFLD) and vitamin D deficiency on glycemic control in
children and adolescents has not been fully elucidated. Poor
glycemic control remains a growing problem in patients with type
1 (T1D) or type 2 diabetes (T2D) [4] despite improvements in
insulin formulation, delivery and adjunctive therapies [5]. A recent
national study reported that a high proportion of youth with
diabetes had elevated hemoglobin A1c (HbA1c) values, with 17%
of patients with TIDM and 27% of those with T2DM showing
significantly poor control, defined as HbA1c $9.5% [4].
NAFLD is the most common form of liver dysfunction in
children [6], and the leading cause of elevated liver enzymes in
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obese youth [7]. Even though its prevalence is rising in parallel
with the prevalence of childhood obesity [8], its role in poor
glycemic control in diabetes is unknown. NAFLD represents a
spectrum of conditions characterized by macrovesicular hepatic
steatosis and little or no exposure to alcohol [8]. The hepatic
pathology encompasses a range from isolated fatty infiltration to
steatohepatitis, advanced fibrosis, and cirrhosis [6].
NAFLD has been strongly associated with vitamin D deficiency
[9,10], IR [11], prediabetes [12], and T2D [10,13–17]. Several
studies have reported associations between liver dysfunction and
low vitamin D levels [9,10,18–20] on one hand, and liver
dysfunction and poor glycemic control on the other [21]. Our
group showed that hepatic dysfunction, characterized by elevated
transaminases, was associated with vitamin D deficiency and poor
glycemic control in children and adolescents with T2D, but not
T1D [22]. This has led to the hypothesis that mild hepatic
dysfunction could impair the conversion of vitamin D to 25-
hydroxyvitamin D [25(OH)D], and consequently result in vitamin
D deficiency. The resultant vitamin D deficiency is believed to
impair insulin sensitivity [23].
Vitamin D deficiency is prevalent in children and adolescents
with diabetes mellitus [22,24,25]. The etiology of this vitamin D
deficiency is often attributed to the lack of sun exposure, poor
intake of vitamin D-containing foods such as salmon, or due to
either volumetric dilution [26], or sequestration of vitamin D in fat
depots [27]. However, a crucial step in the metabolism of vitamin
D, the hydroxylation of vitamin D at the 25 position, occurs in the
liver. The role of NAFLD on this critical step in vitamin D
metabolism in children and adolescents with diabetes has not been
fully studied [22]. Equally, the effects of the resultant vitamin D
deficiency on glycemic control in these patients are unclear. A
study in healthy, non-diabetic adults with normal glucose
tolerance using the hyperglycemic clamp technique showed a
positive correlation of 25(OH)D level with insulin sensitivity [23].
Extrapolation of the data suggested that increasing the serum
concentration of 25(OH)D from 25–80 nmol/L would increase
insulin sensitivity by 60% [23], indicating that perhaps vitamin D
supplementation offers promise as an adjunctive therapy for those
with diabetes mellitus [28]. Recent studies in non-diabetic children
and adolescents showed that low levels of 25(OH)D were
associated with increasing insulin resistance in patients at risk for
diabetes [29], while a 12-week study involving children, adoles-
cents and young adults with T1D showed improved HbA1c level
following a combined vitamin D and calcium supplementation
protocol [30].
Therefore, to achieve the elusive goal of glycemic control in
diabetes, euglycemia, it is necessary to evaluate the role of
comorbid states such as hepatic dysfunction and vitamin D
deficiency on glycemic control. Even though our group showed
that hepatic dysfunction was associated with vitamin D deficiency
and poor glycemic control in patients with T2D and not in those
with T1D, the effects of vitamin D supplementation on the
coexistence of hepatic dysfunction, vitamin D deficiency, and poor
glycemic control have not been adequately studied in children and
adolescents with either T1D or T2D. We hypothesize that vitamin
D supplementation would improve vitamin D status, reduce
hepatic dysfunction, and in turn lead to improved glycemic control
in children and adolescents with diabetes mellitus. The study’s aim
was to determine the effect of vitamin D supplementation on ALT,
HbA1c, and 25(OH)D in patients with vitamin D deficiency and
either T1D or T2D.
Subjects and Methods
Ethics Statement
The study protocol was approved by the University of
Massachusetts Institutional Review Board. All patient records
and information were anonymized and de-identified prior to
analysis.
Subjects
The clinical records of children and adolescents of ages 3–18
years who were treated for T1D and T2D at the Children’s
Medical Center of the University of Massachusetts between 2007
and 2013 were reviewed. Subjects were included if they had a
diagnosis of diabetes for .12 mo, had HbA1c and 25(OH)D
obtained simultaneously, and were on no vitamin D or calcium
supplements. Subjects were excluded if they had vitamin D or
calcium supplementation at baseline, or the disorders of calcium
metabolism, hemoglobinopathies, or malabsorption syndrome
such as celiac disease. Eighty-eight subjects with T1D (46 females,
42 males) and 43 subjects with T2D (26 females and 17 males)
fulfilled these criteria (Table 1). The diagnosis of T2D was based
on fasting blood glucose of $7 mmol/L (126 mg/dL), and/or 2-
hour postprandial glucose of $11.1 mmol/L (200 mg/dL), and/
or random blood glucose of $11.1 mmol/L (200 mg/dL) with
symptoms of polyuria and/or polydipsia. All patients with T2D
had negative results for T1D-associated antibodies (insulin, islet
cell, glutamic acid decarboxylase, and insulinoma associated-2).
Because 25(OH)D level could vary with sunlight exposure, we
categorized each subject’s visit according to the seasons as follows:
fall (September 22–December 21), winter (December 22–March
21), spring (March 22– June 21), and summer (June 22-September
21) [31]. All subjects with T1D received insulin only. Of the 43
patients with T2D, 17 patients received a combination of insulin
and metformin, 15 patients received metformin only, while 8
patients received insulin monotherapy.
The Procedure for Vitamin D Therapy
The rationale for the vitamin D supplementation in these
patients was based on recent reports of high prevalence of vitamin
D deficiency in children and adolescents with either T1D or T2D
[22,24,25]. It is the standard practice at the Children’s Medical
Center to monitor the vitamin D status of children and adolescents
with diabetes mellitus during patients’ yearly blood draw for the
evaluation of complications of diabetes mellitus, or at one of the
patients’ quarterly visits for routine diabetes care. Patients with
serum 25(OH)D concentration of ,50 nmol/L were started on
vitamin D supplementation using either ergocalciferol or chole-
calciferol with the aim of raising the 25(OH)D level to .75 nmol/
L.
All participants received either ergocalciferol or cholecalciferol
for a period ranging from 8 weeks for those receiving 7000 IU/
day, through 12–16 weeks for subjects receiving 400–4000 IU/
day as shown in Table 2. The dose of vitamin D was based on
patient’s age and weight according to reports showing that
25(OH)D response to vitamin D supplementation is directly
related to dose and body size [32].
Anthropometry
Height was measured to the nearest 0.1 cm using a wall-
mounted stadiometer (Holtain Ltd, Crymych, Dyfed, UK). Weight
was measured to the nearest 0.1 kg using an upright scale. Body
mass index (BMI) was derived using the formula weight/height2
(kg/m2), and expressed as SDS for age and gender based on
National Center for Health Statistics (NCHS) data [33].
Vitamin D and Glycemic Control in Children and Adolescents
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Biochemical Studies
Data were collected from quarterly HbA1c estimation during
clinic visits. Data on serum concentrations of alanine transaminase
(ALT) were obtained simultaneously with HbA1c during routine
clinic visit before and after vitamin D supplementation in both
T1D and T2D patients. Specifically, ALT, 25(OH)D and other
laboratory studies were estimated annually or bi-annually, as part
of a routine screening protocol for complications of diabetes
mellitus. Patients with vitamin D deficiency were started on
vitamin D supplementation, and had a follow up laboratory
evaluation for 25(OH)D level at their follow up quarterly visit.
Vitamin D supplementation was either discontinued if vitamin D
levels became normal upon retesting, or supplementation was
continued for another cycle of treatment to attain normal vitamin
D status. Data were collected on HbA1c levels obtained 3 months
prior to the date of vitamin D supplementation, at the time of the
initiation of vitamin D supplementation, and at +3mo, +6mo, and
+9mo for the evaluation of the temporal effect of vitamin D
supplementation on HbA1c levels.
Assays
Hemoglobin A1c was measured by DCA 2000+ Analyzer
(Bayer, Inc., Tarrytown, NY, USA) based on Diabetes Control
and Complications Trial standards [34]. Serum levels of 25(OH)D
were analyzed using 25-hydroxy chemiluminescent immunoassay
(DiaSorin Liaison; Stillwater, Minnesota), which has a 100% cross-
reactivity with both metabolites of 25(OH)D namely, 25(OH)D2
and 25(OH)D3 and thus measures total serum 25(OH)D content.
Its functional sensitivity is 10 nmol/L (4 ng/mL), and its intra-
and inter-assay coefficients of variation are 5% and 8.2%
respectively.
Vitamin D Status
Vitamin D sufficiency was defined as a 25(OH)D concentration
$30 ng/mL (75 nmol/L); vitamin D insufficiency as 25(OH)D of
20 to 29.9 ng/mL (50 to 75 nmol/L); and vitamin D deficiency as
25(OH)D level ,20 ng/mL (50 nmol/L) according to the
Endocrine Society criteria [35].
Statistical Analyses
Statistical analyses were performed using the Predictive
Analytics SoftWare v.21 (IBM Corporation, Armonk, NY).
Table 1. Comparison of the characteristics of patients with type 1 diabetes vs. type 2 diabetes.
Parameters Type 1 Diabetes (n=88) Type 2 Diabetes (n=43) p
Age (years) 12.663.6 16.262.2 ,0.001
Sex: males (%) 42 (47.7%) 17 (39.5%) 0.38*
Race: white (Non-Hispanic) (%) 73 (83.0%) 23 (53.5%) 0.001*
Height SDS (baseline) 0.0461.1 0.261.2 0.57
Height SDS (3mo) 0.0461.1 0.0461.2 1.0
Weight SDS (baseline) 0.6961.0 2.360.9 ,0.001
Weight SDS (3mo) 0.7161.0 2.361.0 ,0.001
Body Mass Index SDS (baseline) 0.8060.9 2.260.6 ,0.001
Body Mass Index SDS (3mo) 0.8160.8 2.1460.7 ,0.001
Alanine Transaminase (U/L) 19.266.2 48.3647.4 0.001
25(OH)D level (nmol/L) 53.7614.6 41.2615.3 ,0.001
25(OH)D level (nmol/L) in Whites 54.0614.3 42.0615.9 0.004
Percentage Vitamin D Deficiency
[25(OH)D ,50 nmol/L] (%)
33 (37.5%) 31 (72.1%) ,0.001*
Hemoglobin A1c (%) 8.561.2 8.562.9 0.94
Seasons (Summer-Fall) 50/88 (56.8%) 17/43 (39.5%) *0.063
Duration of Diabetes Mellitus 2.961.2 2.0361.29 0.001
* =p values by Chi Square for proportions; SDS = standard deviation score; 25(OH)D = 25hydroxyvitamin D.
doi:10.1371/journal.pone.0099646.t001
Table 2. Summary of Patients’ Vitamin D Treatment Plan.
Treatment Plan Number of Subjects
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Means, standard deviations, and percentages were calculated for
descriptive summary statistics. The values for ALT were log
transformed before analysis to approximate normal distributions.
Comparisons between independent means were made using two-
tailed Student’s t test and ANOVA. Non-independent measure-
ments over time were compared using paired t test and repeated-
measures ANOVA. Proportions were compared using Chi square
test; Fisher’s exact test was used where marginal totals were ,5.
Height, weight, and BMI were expressed as a standard deviation
score (SDS).
Power analysis. The study’s primary goal was to detect
significant changes in HbA1c in subjects with either T1D or T2D
during the 3 mo period of vitamin D supplementation, and
secondarily to determine if there was a persistence of the changes
in HbA1c over a 9 mo period. The small effect size of +0.03%
change in HbA1c during the 3 mo of vitamin D supplementation
in the 88 patients with T1D yielded a power of 7.5%, while the
clinically-significant effect size of 20.6% in 37 subjects with T2D
who had pre- and post-treatment values for HbA1c yielded a
power of 60.4% at a p value of 0.024. Further extrapolation
showed that 1,982 subjects with T1D would be needed to achieve
a power of 60.4%; while 3,175 patients with T1D, and 58 patients
with T2D would be needed to achieve a power of 80%.
Results
One hundred and thirty one subjects of ages 3–18 years (male
13.863.4 years, female 13.763.8, p = 0.80) were studied. This
consisted of 88 subjects (42 males, 46 females) with T1D of mean
age 12.663.6 years (males 13.163.5; females 12.163.6, p = 0.23);
and 43 subjects (17 males, 26 females) with T2D of mean age
16.262.2 years (males 15.862.2; females 16.462.2, p= 0.36)
(Table 1).
At baseline, 72.1% of patients with T2D had vitamin D
deficiency compared to 37.5% of T1D patients (p,0.001).
Patients with T2D had significantly higher values than those with
T1D for BMI SDS (2.260.6 vs. 0.8060.9, p,0.001), ALT
(48.3647.4 vs. 19.266.2, p = 0.001), but lower mean 25(OH)D
level (41.2 nmol/L 615.3 vs. 53.7614.6, p,0.001), and no
difference in HbA1c (8.562.9% vs. 8.561.2, p= 0.94) and total
daily dose (TDD) of insulin per kg body weight (0.85 units/kg
60.4 vs. 0.8860.3, p = 0.48) (Table 3).
At 3 months, following vitamin D supplementation, 25(OH)D
increased significantly in patients with T1D from a baseline of
53.3614.6 nmol/L to a peak of 67.6620.6 at 3 mo, and then
decreased to 62.4618.4 nmol/L (ANOVA p,0.001) (Figure 1).
Similarly, in patients with T2D, 25(OH)D rose significantly from a
baseline value of 41.8615.0 nmol/L to a peak of 60.7627.7 at 3
months and then subsequently decreased to 49.2616.6 nmol/L
(ANOVA p,0.011). There was neither a change in the TDD of
insulin per kg body weight in either T1D or T2D, nor in the TDD
of metformin per kg body weight in T2D patients (Table 3).
Following vitamin D supplementation, there was a significant
decrease in ALT in T2D (50.7650.9 U/L to 35.0631.0,
p = 0.012), but not in T1D (18.066.0 U/L to 15.762.0
(p = 0.46) (Figure 2).
An analysis of the anthropometric changes in the subjects
during the 3-month period of vitamin D supplementation showed
no differences in weight SDS in either the T1D (0.7061.0 to
0.7161.0, p = 0.31) or T2D (2.3160.96 to 2.2660.96, p= 0.13)
cohort. In contrast, there was a significant decrease in BMI SDS in
patients with T2D (2.2160.62 to 2.1460.66, p = 0.015), but not in
patients with T1D (0.8060.88 to 0.8160.84, p = 0.61).
A comparison of changes in HbA1c level over a period of 9 mo
from the time of the initiation of vitamin D supplementation in
subjects with either T1D or T2D showed a significant difference in
HbA1c between the subjects with T1D and those with T2D
(ANOVA p=0.011). A focused analysis of the changes in HbA1c
over the 9-month period showed a statistically significant, but
clinically non-significant increase in HbA1c from baseline to 9 mo
(p = 0.001) in the T1D cohort, while the patients with T2D had no
change in A1c (p = 0.52). A closer examination of the HbA1c
trends during the 9 mo showed that in patients with T1D, HbA1c
levels increased consistently over time from 8.561.2 through
8.961.2% (ANOVA p=0.001), while in patients with T2D, the
HbA1c value decreased at the beginning of the supplementation
(8.562.9% at baseline through 7.762.5% at 3 mo) but slowly
returned toward the baseline value of 8.262.3% at the end of 9
months (Figure 3). To investigate whether pre-treatment excur-
sions in HbA1c accounted for the changes in HbA1c described
above for T1D and T2D, we compared the mean of the HbA1c
levels drawn 3 mo before the start of vitamin D supplementation
to the mean of the baseline HbA1c drawn just before the start of
vitamin D therapy. There were no significant differences in
HbA1c values in T1D (8.461.3% vs. 8.561.2, p = 0.57), and in
T2D (8.963.3 vs. 8.562.9, p = 0.26).
Discussion
This study evaluated the effects of vitamin D supplementation
on hepatic dysfunction and glycemic control in children and
adolescents with vitamin D deficiency and either T1D or T2D. At
baseline, a greater proportion of subjects with T2D were obese,
and had both vitamin D deficiency and elevated ALT levels
compared to those with T1D. The 3-mo period of vitamin D
supplementation in subjects with T2D was associated with
Table 3. Comparison of the changes in the doses of insulin and metformin during the period of vitamin D supplementation.
Parameters Type I Diabetes (n=88) p Type 2 Diabetes (n =43) p
Time (months) 0 3 0 3
TDD of insulin (units) 48.0626.4 49.4626.7 0.008 75.6636.1 73.1635.8 0.23
TDD of insulin per kg
body weight (units/kg)
0.9060.3 0.9160.3 0.54 0.8560.4 0.8060.41 0.067
TDD of metformin (mg) N/A N/A N/A 1105.06687.4 122.36670.0 0.052
TDD of metformin per kg
body weight (mg/kg)
N/A N/A N/A 10.7167.5 12.368.0 0.060
TDD= total daily dose.
doi:10.1371/journal.pone.0099646.t003
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significant reduction in BMI SDS, ALT, and a clinically-
significant decrease in HbA1c which was followed by a gradual
return toward pretreatment HbA1c values. These reductions in
BMI SDS, ALT, and HbA1c [36] in T2D patients were not
associated with significant changes in the doses of either insulin or
metformin. These data and our earlier report [22] suggest that
vitamin D deficiency may be associated with mild hepatic
dysfunction which could in turn impair glycemic control in
patients with T2D. The normalization of serum vitamin D
concentration through vitamin D supplementation appeared to
transiently improve glycemic control in patients with T2D.
Our data are in agreement with studies showing a higher
prevalence of vitamin D deficiency in pediatric patients with T2D
compared to those with T1D [37]. The clinically-significant
reduction in HbA1c in our T2D cohort (Figure 2) is consistent
with reports of significant associations between vitamin D and
glycemic control in T2D [38], as well as earlier reports linking
vitamin D deficiency with glucose intolerance [39], hyperinsulin-
emia [40], obesity [41], and T2D. This clinically-significant
reduction in HbA1c in subjects with T2D is similar to the findings
of a meta-analysis [36] on the effect of exercise on HbA1c in
patients with T2D, which reported a decrease in HbA1c of 0.6%,
with associated significant reductions in both visceral and
subcutaneous adipose tissues in the study patients.
Vitamin D Deficiency and Type 1 Diabetes
Though vitamin D deficiency has been associated with
increased risk of developing T1D [42,43], the relationship between
25(OH)D and glycemic control in patients with T1D is not fully
understood. Our previous study [22] found no significant
relationship between 25(OH)D and HbA1c in patients with
T1D, while this study found a statistically significant, but clinically
non-significant increase in HbA1c value following vitamin D
supplementation. These results differ from the conclusions of a
study in children, adolescents, and young adults with T1D which
found a significant reduction in HbA1c level following a
supplementation regimen consisting of both vitamin D and
calcium [30]. It is possible that vitamin D alone has no significant
role on improving glycemic control in patients with T1D.
Vitamin D Deficiency and Type 2 Diabetes
There is no consensus on the effect of vitamin D supplemen-
tation on HbA1c level in T2D. Even though previous studies
[22,44,45] had reported strong inverse relationship between
25(OH)D and HbA1c, this association alone is not enough to
demonstrate a cause and effect relationship. Evidence from two
randomized controlled trials (RCT) suggests that vitamin D
supplementation effectively reduces insulin resistance (IR) [46,47],
but three smaller RCTs [48–50] of vitamin D supplementation in
patients with T2D reported no change in HbA1c following
vitamin D supplementation. A closer examination of these three
Figure 1. Graph showing a rise in the serum concentrations of 25-hydroxyvitamin D [25(OH)D] during vitamin D supplementation
in patients with either type 1 diabetes or type 2 diabetes. In patients with type 1 diabetes, 25(OH)D rose from a baseline of 53.3614.6 nmol/L
to a peak of 67.6620.6 at 3 mo, and then decreased to 62.4618.4 (ANOVA p,0.001). In patients with type 2 diabetes 25(OH)D rose from a baseline
value of 41.8615.0 to a peak of 60.7627.7 at 3 months and then decreased to 49.2616.6 (ANOVA p= 0.011).
doi:10.1371/journal.pone.0099646.g001
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RCTs showed several limitations: (1) all three studies were
underpowered (only 16–20 participants per arm), (2) only one
study [50] was designed for glycemic outcomes, but it recruited
only about half of the planned cohort, and studied patients with
normal 25(OH)D levels; (3) only one study [48] reported baseline
use of diabetes medications; however, in that study metformin use
rate was much higher in the vitamin D arm; (4) changes in diabetes
medications were not reported and were not taken into account in
the analyses; and (5) all three trials used large infrequent doses of
vitamin D. Two recent randomized studies reported improved
glycemic control in patients with T2D who either received vitamin
D alone [51] or vitamin D fortified yogurt drink [52] while
another study reported decreased levels of inflammatory markers
following vitamin D supplementation in patients with T2D [53].
However, a Japanese study reported no change in HbA1c
following 2000 IU per day of vitamin D3 with calcium for 24
weeks in patients with T2D [54]. Thus, the effects of vitamin D
supplementation on glycemic control in patients with T2D are
unclear in adults, and more so in children and adolescents where
there are only a few published studies.
There was a significant decrease in BMI SDS in patients with
T2D following vitamin D supplementation. The high prevalence
of obesity and vitamin D deficiency at baseline in subjects with
T2D is consistent with a report that characterized vitamin D
deficiency as a risk factor for obesity and T2D [55]. The decrease
in BMI SDS concurs with earlier studies indicating that vitamin D
repletion could potentiate weight loss and improve metabolic
markers [47,56,57]. Vitamin D is believed to regulate adipocyte
apoptosis leading to decreased fat mass [58,59]. This vitamin D-
associated weight loss may have contributed to the significant
decrease in ALT concentrations in our T2D cohort.
Vitamin D Deficiency and Alanine Transaminase
There was a significant decrease in ALT following vitamin D
supplementation in patients with T2D compared to those with
T1D. Several studies have reported an association between liver
enzymes or calculated surrogate measures of NAFLD, such as fatty
liver index, and the incidence of diabetes mellitus [13–16]. Recent
studies suggest that NAFLD predicts prediabetes [12], and that the
resolution of fatty liver could reduce the risk of incident diabetes
mellitus [18]. We previously showed a strong inverse relationship
between ALT and 25(OH)D in children and adolescents with T2D
[22], while this present study reports a significant decrease in ALT
levels in patients with T2D who received vitamin D supplemen-
tation for the management of hypovitaminosis D.
The mechanism of the transient, clinically-significant improve-
ment in glycemic control in patients with T2D during the period of
vitamin D supplementation is not clear. Vitamin D supplemen-
tation has been shown to improve b-cell function [23] and the
augmentation of insulin synthesis and secretion once it is activated
to its active form, 1,25-dihydroxyvitamin D, by 1a-hydroxylase
enzyme which is expressed in b cells [60] [61–63]. This study
however, suggests that an improvement in hepatic dysfunction, as
shown by reduced ALT, could also be associated with an
improved glycemic control.
One of the limitations of our study is its retrospective nature
which could have introduced selection bias as only patients who
fulfilled the inclusion and exclusion criteria were studied. We also
Figure 2. Bar graph showing the temporal change in the levels of alanine transaminases (ALT) following vitamin D
supplementation. ALT decreased from 18.066.0 U/L to 15.762.0 (p = 0.46) in patients with type 1 diabetes; and from 50.7650.9 to 35.0631.0
(p = 0.012) in those with type 2 diabetes.
doi:10.1371/journal.pone.0099646.g002
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did not directly evaluate subjects’ compliance with their vitamin D
therapy. However, the post-treatment vitamin D levels were
significantly elevated in patients with either T1D or T2D. Another
limitation was that the vitamin D supplementation was not
continued for longer than three months, and thus it was unclear
whether the effect of vitamin D supplementation on glycemic
control could have been sustained over a longer period of time.
The lack of a relationship between ALT and 25(OH)D in T1D
patients may be due to the fact that a fewer number of patients
with T1D had ALT measured as compared to the larger
proportion of patients with T2D who had ALT values. Specifi-
cally, forty two (47.7%) of the patients with T1D, and 36 (83.7%)
of the subjects with T2D had ALT measured at baseline, while 12
(13.6%) of T1D and 29 (67.4%) of the T2D patients had ALT
values following vitamin D supplementation. Another reason for a
lack of an association between ALT and 25(OH)D could be due to
the fact that subjects with T1D had normal mean serum ALT
concentration at baseline compared to patients with T2D.
The strengths of this study stem from the fact that both the
patients with either T1D or T2D received their care within the
same clinical system, which is located in a similar geographical
area around latitude 42u N, thus ensuring similar levels of
insolation around the year. We had a relatively good sample size to
enable us determine the differences in the various parameters
studied. The availability of post-treatment 25(OH)D values
confirmed that the subjects received the interventional therapy,
while the availability of serial HbA1c values enabled us to establish
a longitudinal model for the investigation of the duration of the
glycemic effects of vitamin D supplementation on HbA1c and
ALT in both T1D and T2D. Even though this is a retrospective
study, it provides the much needed data on the effect of routine
vitamin D supplementation on HbA1c, 25(OH)D, and ALT values
in children and adolescents with either T1D or T2D. Such data
will help establish the rationale for further investigation on the
effects of vitamin D supplementation on these parameters in
children and adolescents with diabetes mellitus.
Conclusions
This study demonstrates that routine vitamin D supplementa-
tion in patients with diabetes mellitus is associated with a
significant reduction in BMI SDS, ALT, and an initial,
clinically-significant reduction in HbA1c in patients with T2D,
but not T1D. The changes in these parameters were not associated
with significant changes in the doses of either insulin or metformin.
Even though these findings suggest that vitamin D deficiency could
impair hepatic processes that promote b-cell function and
glycemic control in patients with T2D; and that this hepatic
dysfunction could be ameliorated by vitamin D supplementation
with resultant improvement in glycemic control, our data are not
adequate to confirm these conclusions. Further randomized
controlled trials are warranted to determine the effect of vitamin
D supplementation on glycemic control in T2D, and the optimal
Figure 3. A 9-month analysis of the changes in hemoglobin A1c (HbA1c) level following a three-month vitamin D supplementation
in patients with either type 1 diabetes or type 2 diabetes. There was a statistically-significant, but clinically non-significant rise in HbA1c level
over 9 months in T1D (8.561.2 through 8.961.2%, ANOVA p= 0.001). In T2D, there was a clinically significant decrease in HbA1c [36] in the first 3
months (during the period of vitamin D supplementation) from 8.562.9% at baseline through 7.762.5% at 3 mo, followed by a slow return to
pretreatment values of 8.262.3% at 9 mo. There was however, no statistical significant difference in HbA1c between the time points (ANOVA
p= 0.52).
doi:10.1371/journal.pone.0099646.g003
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dose of adjunctive vitamin D therapy for the maintenance of long-
term glycemic control in children and adolescents with diabetes
mellitus.
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